Verified employee & interview reviews

Sanofi India Reviews

Mumbai, Maharashtra

4.7/ 5

3 reviews

Sanofi India Limited is a leading multinational pharmaceutical company and a critical subsidiary of the global healthcare leader, Sanofi S.A. Established in India in 1956, the company was formerly known as Aventis Pharma Limited before rebranding to Sanofi India Limited in May 2012. Headquartered in Mumbai at Sanofi House in Powai, the company has built a legacy of nearly seven decades, aligning itself with India's healthcare needs through extensive research and development, manufacturing, and strategic partnerships. The company's core operations revolve around the manufacturing and trading of a wide array of pharmaceutical products. It holds a dominant position in several therapeutic areas, most notably in diabetes care, where it offers flagship brands like Lantus, Toujeo, and Soliqua. Beyond diabetes, Sanofi India provides essential treatments in cardiology (Cardace, Lasix), thrombosis (Clexane), the central nervous system (Frisium), and anti-histamines (Allegra). Its diverse portfolio also includes well-known consumer brands such as Combiflam, Enterogermina, and Dulcoflex. While the company recently completed a strategic demerger of its Consumer Healthcare business into a separate legal entity, Sanofi Consumer Healthcare India Limited, to enhance operational focus, it remains a powerhouse in the prescription medicine market. Sanofi India operates a state-of-the-art manufacturing facility in Goa, which serves as a hub for producing high-quality medicines for both domestic and international markets, exporting to approximately 24 countries. The company employs roughly 4,000 people in India and is driven by an "AI-powered biopharma" strategy to accelerate scientific breakthroughs. Financially, Sanofi India is publicly traded on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). As of early 2026, the company maintains a robust financial profile with a market capitalization exceeding INR 7,700 crore. For the fiscal year ending March 31, 2023, it reported a revenue of approximately INR 2,920 crore. Sustainability and ethics are central to Sanofi’s corporate identity. The company integrates Environmental, Social, and Governance (ESG) frameworks into its business model, focusing on affordable access to healthcare, community engagement, and minimizing environmental impact. Led by a dedicated leadership team in India, the company continues to focus on "Chasing the Miracles of Science" to improve patient outcomes. Through its commitment to innovation and long-standing presence, Sanofi India remains a vital pillar of the Indian pharmaceutical industry, dedicated to providing life-changing treatments and vaccines to millions of patients across the country.